Validation of a Diagnostic Algorithm of Giant Cell Arteritis (ECHORTON)

Poitiers University Hospital

Status

Completed

Conditions

Giant Cell Arteritis

Treatments

Other: color Doppler ultrasound and TAB in case of CDU negative

Study type

Interventional

Funder types

Other

Identifiers

NCT02703922

ECHORTON

Details and patient eligibility

About

Giant cell arteritis (GCA or temporal arteritis or cranial arteritis) or Horton disease is a vasculitis that occurs in older adults, affecting vessels of medium and large caliber. The diagnosis of GCA is a challenge for general practitioners and specialists. Since 1970, it is based on a combination of clinical, biological and histological signs. Temporal artery biopsy (TAB) was the reference method until recently. However, TAB has many drawbacks. Therefore, researches of the past 20 years have been intended to develop alternative diagnostic methods. This was notably the case of the color Doppler ultrasound (CDU) since the description by Wolfgang Schmidt of the halo sign. Although European and British recommendations put CDU as second line method, many authors suggest the possibility to do without TAB in many cases. In addition, many practitioners believe that it is not "ethical" to use an invasive unprofitable procedure like TAB, and have already been using CDU in their routine practice. However, no diagnostic algorithm validating this approach in a prospective series has been published to date. Therefore, the present study aim at validating a diagnostic algorithm of giant cell arteritis using color Doppler imaging of temporal arteries and cervicocephalic axes as first screening method.

Enrollment

165 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥ 50 years
C reactive protein (CRP) above normal
Suspected of GCA according to clinician expertise and / or aortitis arteritis or of one or more arteries from the aorta imaging (CT angiography, magnetic resonance angiography or positron emission tomography TDM18FDG)
Benefiting from Social Security or receiving it via a third party
have given their participation agreement by understanding and accepting the constraints of the study

Exclusion criteria

Received corticosteroid dose ≥ 20 mg of prednisone equivalent for more than 7 days in the month before inclusion
Underwent temporal artery biopsy before color Doppler ultrasound
History of GCA
Terminal palliative phase or suffering from a disease or comorbidities such as life is involved in less than a year
Patient with severe cognitive impairment
Patient that can not be followed by the investigator for the duration of the study
Refusal to participate in the study
With enhanced protection (namely those deprived of liberty by a court or administrative order, patient staying in a health or social institution, under legal protection, and patients in emergencies)
Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception
Participating in another clinical trial.